^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Immunomodulator

Related drugs:
17h
HYDROSAPL: HYDROxychloroquine in Syndrome Primary AntiPhospholipid (clinicaltrials.gov)
P2, N=0, Withdrawn, Assistance Publique - Hôpitaux de Paris | N=110 --> 0 | Recruiting --> Withdrawn
Enrollment change • Trial withdrawal
|
hydroxychloroquine
23h
Low-Dose Naltrexone For ME/CFS: Dose-Finding (clinicaltrials.gov)
P2, N=75, Not yet recruiting, University of Alabama at Birmingham | Initiation date: Apr 2026 --> Jul 2026
Trial initiation date
1d
Rewiring Metal-Dependent Cell Death to Unlock Immunotherapy in Colorectal Cancer. (PubMed, Nano Lett)
Decitabine restores gasdermin E expression to couple oxidative stress with caspase-3-mediated pyroptosis, while chlorogenic acid repolarizes tumor-associated macrophages toward a pro-inflammatory phenotype. This coordinated multimodal cell-death cascade establishes a self-amplifying immunogenic circuit that suppresses tumor growth, sensitizes CRC to ICB, and elicits systemic antitumor immunity.
Journal • PD(L)-1 Biomarker • IO biomarker
|
CASP3 (Caspase 3) • GSDME (Gasdermin E)
|
decitabine • chlorogenic acid
1d
Sarcoidosis-Induced Hypercalcemia in a Patient With Multiple Endocrine Neoplasia Type 2A (MEN2A) Syndrome Harboring the C609Y REarranged During Transfection (RET) Mutation. (PubMed, AACE Endocrinol Diabetes)
Patient was managed acutely with calcitonin and was started on prednisone and hydroxychloroquine. The co-occurrence of both MEN 2A and sarcoidosis is rare, adding an unexpected layer of complexity to the diagnosis. The rarity of sarcoidosis co-occurring with MEN 2A highlights the importance of considering a broad differential diagnosis, even in patients with known genetic syndromes, to ensure accurate management.
Journal
|
RET (Ret Proto-Oncogene)
|
RET mutation
|
prednisone • hydroxychloroquine
2d
Enrollment closed
|
Jakafi (ruxolitinib)
6d
TAK-012-1501: A Study of GDX012 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
P1/2, N=16, Terminated, Takeda | Trial completion date: May 2026 --> Nov 2025 | Active, not recruiting --> Terminated; Sponsor decision (No safety concern)
Trial completion date • Trial termination
|
cyclophosphamide • fludarabine IV • TAK-012
6d
LC/MS-Based Phytochemical Profiling and Immunomodulatory Evaluation of Three Medicinal Plants With Anticancer and Antibacterial Activities. (PubMed, Chem Biodivers)
aureum was enriched in ferulic acid, rutin, chlorogenic acid, and p-coumaric acid, whereas A. mexicana contained veratric acid, luteolin, and apigenin...These findings highlight a clear relationship between phytochemical composition and biological activity, indicating that these medicinal plants may serve as promising sources of multitarget phytotherapeutic agents. Further in vivo studies and bioactive compound isolation are required to validate their therapeutic potential.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein)
|
chlorogenic acid
7d
San-Huang-Chai-Zhu formula alleviates intrahepatic cholestasis through PPARα-mediated bile acid homeostasis and MKK4/JNK pathway. (PubMed, Cytotechnology)
The therapeutic potential of SHCZF was evaluated in alpha-naphthylisothiocyanate (ANIT)-induced IC rat model, with ursodeoxycholic acid (UDCA) used as positive control...Importantly, GW6471 altered the regulatory effects of SHCZF on MKK4/JNK pathway and bile acid homeostasis. SHCZF improves IC by regulating PPARα-mediated bile acid homeostasis and MKK4/JNK pathway.
Journal
|
MAP2K4 (Mitogen-Activated Protein Kinase Kinase 4) • PPARA (Peroxisome Proliferator Activated Receptor Alpha)
8d
CK0801 for Treatment of Aplastic Anemia (clinicaltrials.gov)
P2, N=12, Not yet recruiting, Cellenkos, Inc.
New P2 trial
|
CK0801